Merck (MRK): Rep. Lisa C. McClain (MI09) disclosed a sale $1K–$15K

$1,001–$15,000

Reported range · official band, not an exact amount

39 days

Disclosure lag

Traded

Aug 4, 2025

Disclosed

Sep 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 7, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Sep 26, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
3. Oct 29, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
4. Mar 19, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
5. May 30, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
6. Jun 6, 2025FDAFDA drug approval: Keytruda
7. Jun 9, 2025FDAFDA drug approval: Enflonsia
8. Jun 12, 2025FDAFDA drug approval: Keytruda
9. Jun 13, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
10. Jun 16, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
11. Jun 24, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
12. Jul 11, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
13. Jul 21, 2025FDARecall: Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway,…
14. Jul 24, 2025FDAFDA drug approval: Keytruda
15. Aug 4, 2025 · this disclosureCongressDisclosed sale of MRK — reported range $1,001 - $15,000

What came next

1. Aug 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Aug 14, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
3. Aug 28, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
4. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
5. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
6. Sep 23, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
7. Oct 15, 2025FDAFDA drug approval: Bla761495
8. Oct 24, 2025FDAFDA drug approval: Winrevair
9. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
10. Nov 3, 2025InsiderOfficer sold ~$720K of MRK shares in the open market
11. Nov 10, 2025InsiderOfficer sold ~$616K of MRK shares in the open market
12. Nov 21, 2025FDAFDA drug approval: Keytruda
13. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Rep. Lisa C. McClain (MI09)

• House Clerk periodic transaction report at CACI (CACI)Oct 12, 2026
• House Clerk periodic transaction report at Caterpillar (CAT)Oct 12, 2026
• House Clerk periodic transaction report at Immunitybio (IBRX)Oct 12, 2026
• House Clerk periodic transaction report at Immunitybio (IBRX)Oct 12, 2026
• House Clerk periodic transaction report at Microsoft (MSFT)Oct 12, 2026

The full history of Rep. Lisa C. McClain (MI09) is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Merck

• SEC Form 144Nov 12, 2026
• SEC Form 144Nov 2, 2026
• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026

Everything OQRO holds on this company is on its MRK page.